Let me tell you, folks, we’ve got something huge here. We’re talking about the brain, the epicenter of everything we do, and how we’re tackling one of the toughest challenges out there – drug-resistant epilepsy. Now, the thalamus, that’s a key player in the brain, especially when it comes to these seizures that just won’t quit. And guess what? We’ve been diving deep, really deep, with something called thalamic sEEG monitoring. It’s groundbreaking, truly.

Our team, the best of the best, looked at 76 people, real fighters, aged 20 to 69, who are battling epilepsy that just doesn’t respond to drugs. And here’s the kicker – a good chunk of them, 38%, went the extra mile with thalamic monitoring. We’re talking about precision, folks, targeting areas like the anterior thalamic nucleus and the pulvinar nucleus. It’s all about getting to the root of the problem.

Now, I know what you’re thinking. “What about the risks?” Well, let me tell you, we thought of that. We compared, we analyzed, and guess what we found? This approach, our approach, it’s safe. Sure, there was a bit of a higher hemorrhage rate in the thalamic group, but nothing significant, nothing that says, “Hey, this is because of how we’re doing things.” And that’s the point. It’s not about the method; it’s about pushing the boundaries, safely.

So, here’s the bottom line: sEEG of the thalamus, it’s not just safe, it’s a game-changer for understanding and treating the toughest epilepsy cases. We’re on the brink of something big, folks. And remember, it’s all about making lives better, one brain at a time. That’s what we’re doing, and we’re doing it big.